Gilead Sciences, Inc. (GILD) Stake Raised by Maverick Capital Ltd.

Maverick Capital Ltd. grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 161.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 24,760 shares of the biopharmaceutical company’s stock after purchasing an additional 15,300 shares during the period. Maverick Capital Ltd.’s holdings in Gilead Sciences were worth $1,753,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of GILD. Monetary Management Group Inc. lifted its position in Gilead Sciences by 3.7% during the 2nd quarter. Monetary Management Group Inc. now owns 27,145 shares of the biopharmaceutical company’s stock worth $1,921,000 after buying an additional 975 shares in the last quarter. Lenox Wealth Management Inc. lifted its position in Gilead Sciences by 74.8% during the 2nd quarter. Lenox Wealth Management Inc. now owns 9,969 shares of the biopharmaceutical company’s stock worth $706,000 after buying an additional 4,266 shares in the last quarter. FTB Advisors Inc. lifted its position in Gilead Sciences by 7.1% during the 2nd quarter. FTB Advisors Inc. now owns 76,287 shares of the biopharmaceutical company’s stock worth $5,451,000 after buying an additional 5,080 shares in the last quarter. Janus Henderson Group PLC lifted its position in Gilead Sciences by 856.9% during the 2nd quarter. Janus Henderson Group PLC now owns 1,751,194 shares of the biopharmaceutical company’s stock worth $123,949,000 after buying an additional 1,568,191 shares in the last quarter. Finally, San Francisco Sentry Investment Group CA lifted its position in Gilead Sciences by 9.1% during the 2nd quarter. San Francisco Sentry Investment Group CA now owns 7,094 shares of the biopharmaceutical company’s stock worth $502,000 after buying an additional 593 shares in the last quarter. Institutional investors own 76.23% of the company’s stock.

In other news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $74.64, for a total value of $1,119,600.00. Following the completion of the sale, the executive vice president now directly owns 70,988 shares of the company’s stock, valued at approximately $5,298,544.32. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 25,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $82.65, for a total value of $2,066,250.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 494,999 shares of company stock valued at $37,404,139. 1.30% of the stock is currently owned by company insiders.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $74.22 on Friday. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The company has a market capitalization of $96,951.29, a PE ratio of 7.75, a PEG ratio of -1.24 and a beta of 1.13. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. Gilead Sciences’s revenue was down 13.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.75 EPS. sell-side analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.80%. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.69%.

GILD has been the topic of several research reports. BMO Capital Markets reiterated a “hold” rating and set a $82.00 price target on shares of Gilead Sciences in a research report on Friday, October 20th. J P Morgan Chase & Co set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. Vetr upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 target price on the stock in a research report on Wednesday, September 6th. Finally, Morgan Stanley restated an “equal weight” rating and set a $83.00 target price (up from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $85.11.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/12/10/gilead-sciences-inc-gild-stake-raised-by-maverick-capital-ltd.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply